Victory for responsible reporting

A High Court case highlights the inadequacies of England's libel laws and should be used as an impetus for major reform.
difficult. Giving the public-interest defence broader scope would deter weak claims that stifle free speech and would allow judges to dismiss meritless complaints earlier in the process -to the benefit of all.
There is still time to make such a change. The bill will undergo fresh rounds of debate and revision later this year. The Libel Reform Campaign, which Nature supports, is urging lawmakers to add a clause that protects stories in the public interest from libel claims unless the reporters have published falsehoods recklessly or maliciously. Its website (www.libelreform.org) gives readers in the United Kingdom a simple way to contact their member of Parliament to add their voice to the calls for greater reform. At a time when the British press is under great scrutiny, and with some elements already in disgrace, no one wants to give reporters a licence to be irresponsible. The proposed clause would still allow truly aggrieved individuals to sue and win. But it would also free brave and principled reporters such as Schiermeier to expose misbehaviour -journalism that is clearly in the public interest -knowing that if their reporting is thorough and fair, they are unlikely to have to go through a similar ordeal. ■ F or more than three years, Nature Publishing Group and Nature reporter Quirin Schiermeier have been fighting a libel claim brought by physicist and engineer Mohamed El Naschie. The defence cost around £1.5 million (US$2.3 million) in legal fees and gobbled up weeks of the time of several employees. Last week, a judge ruled that it was time and money well spent. El Naschie's libel claim was so weak that the judge conceded not a single point to the plaintiff. The Nature article in question, her 91-page ruling declared, was "responsible journalism", accurate in every key detail, and its publication was "of high order of public interest" (see page 149).
The judgment is welcome vindication for Schiermeier, Nature and for good journalism. It upholds the importance of stories that probe bad practices in science -in this case, El Naschie's abuse of his position as editor of a journal to publish his own papers without peer review. But as Schiermeier says (see page 141), the legal victory has even more significance. It should give additional impetus and backing to a campaign to rewrite the antiquated libel laws of England and Wales, which contributed to making El Naschie's feeble claim so difficult and expensive to fight.
Many in the United Kingdom rightly consider the libel laws a national embarrassment, and politicians have vowed to change them. At present, as Nature has pointed out before, the laws tip the scales so far towards the plaintiff -by forcing defendants to prove the truth of all allegations, rather than plaintiffs to prove the falsehood -that London has become a playground for foreign corporations and celebrities who seek to use the courts to burnish their reputations.
Powerful groups and individuals routinely use the threat of a libel suit to deter consumer and advocacy organizations from speaking out about bad products and practices. And the plaintiff-friendly law has had a chilling effect on scientific debate and on journalism. It means that publications such as Nature must perform a painful calculation every time an important but legally sensitive story comes along: is it worth the risk? Nature's victory shows that you can win when your case is strong, but that takes more stamina and deeper pockets than many organizations can muster. And, much as Nature was determined to fight for good journalism and free speech in this case, a fear of the libel laws has in the past forced us to not report stories that we knew to be true and in the interest of our readers and society. Now some relief is in sight. The three major political parties in the United Kingdom support libel reform, and a bill to change the law is working its way through Parliament. The bill includes welcome measures, such as protection for peer-reviewed publications and for discussions at scientific conferences. But for journalism, such as Nature's article on El Naschie, the reform does not go far enough. It extends the existing Reynolds defence, which gives limited protection for reporting that can be shown to be in the public interest and meets a series of other requirements. But winning a case on 'Reynolds' -one of several grounds on which Nature prevailed -is expensive and "The judgment upholds the importance of stories that probe bad practices in science."
Take a stand
Legal actions and oversight are necessary to keep the drug industry in line. P harmaceutical giant GlaxoSmithKline (GSK) agreed last week to settle criminal and civil claims by paying the US authorities a stunning US$3 billion. It is the largest drug-industry settlement in history; the allegations include that the company ran illegal campaigns to promote the prescription of drugs for unapproved uses in children, and published "false and misleading" accounts of clinical studies.
According to the US complaint, GSK also lavished some doctors and academics with "sham consulting fees" and other payments, as well as gifts and attendance at luxury conferences in venues such as Bermuda and Jamaica -sometimes with sailing or deep-sea fishing thrown in -to encourage them to prescribe drugs for off-label uses (see go.nature.com/dbhkht). Speakers could earn $1,000-2,500 per hour to talk at promotional events, with some negotiating 'six packs' of $12,000-worth of talks over two days. One speaker earned about The settlement, which is far from GSK's first, is the latest in a slew of similar payouts by drug companies in the United States over the past few years, with Pfizer, for example, entering into a $2.3-billion settlement in 2009. The pharmaceutical industry as a whole has now overtaken the defence industry's historical lead in penalties paid to the US government.
Some parts of the pharmaceutical industry have been revealed to be riddled with huge pressures on staff to make sales, corporate and individual greed, and a disregard for ethics and the law that seems often to put the interests of shareholders and investors above those of the people the companies are intended to serve. Some observers told Nature that drug companies might write down financial penalties as a cost of doing business. If so, nothing short of jail time will be an effective deterrent.
The GSK settlement does demand that the company enter into a stringent five-year Corporate Integrity Agreement with the US Department of Health and Human Services. Experts in health law say that the contract has real teeth: it puts in place extensive reporting requirements and external oversight, with penalties for failures in compliance, including heavy fines and going as far as exclusion from federal health-care programmes. Importantly, the rules also protect whistle-blowers from retaliation. GSK saw this oversight coming, and has already started to implement reforms.
The stream of revelations from the drug industry is a reminder that researchers and institutions must be vigilant to ward off the potentially corrupting influence of industry funding and practices. Given that the most drug-industry settlements have concerned the off-label market, journals and the media should rigorously assess studies claiming new benefits from existing drugs. One lesson from the GSK case is that flawed or small studies can be exploited by the sales force and a welloiled public-relations machine to advance off-label ambitions.
Pharmaceutical research demands that industry and academia work together, so the temptation to decry all industry involvement as suspicious must also be resisted. At the same time, institutions and researchers must not be naive in their dealings with industry, and must hold themselves and the companies they work with to the highest ethical standards, including full disclosure of links. Rotten apples who accept kickbacks should be investigated and exposed for bringing shame on the research and medical establishments.
The biggest victim of these drug-industry scandals is the public trust that a medicine does what it is claimed to do, and that information on its safety is reliable. Other victims include honest GSK scientists and staff, who were far removed from their company's machinations, and now must feel sick about the pall of suspicion that will inevitably fall over their efforts. This is unfortunate and unfair. But the US action is essential, one that other countries can follow as a model and a landmark on the road to making corporate responsibility less of a slogan, and more of a reality. ■ "Rotten apples who accept kickbacks should be investigated."
Enjoy the moment
The discovery of the Higgs boson is a massive achievement -let's just savour it.
I
t is the kind of breakthrough that comes along once in a generation: scientists have found a long-sought particle. The news comes from CERN, Europe's high-energy physics lab near Geneva, Switzerland, and it quickly travelled around the world. As described on page 147, the particle is almost certainly the Higgs boson, part of the mechanism that endows other fundamental particles with mass.
Outside the field, the announcement has sparked questions about the utility of particle physics and the cost of such experiments. Within it, physicists are anxious about what to do next. But now is not the time for such questions. At this moment, just for a while, we should lean back in our chairs, prop up our feet and savour the achievement.
First predicted almost 50 years ago, the boson and its corresponding field are the final pieces of one of the most successful physical theories in history. The theory has been given the perfunctory name of 'standard model' , but there is nothing standard about it. Its breadth is astonishing -it encompasses all 16 (and now perhaps 17) of nature's fundamental particles, and every fundamental force apart from gravity. And as amazing as its scope is the theory's precision. It predicts the electromagnetic moment of the electron to 12 decimal places, for example, and it has verified hundreds of complex measurements made by experimental physicists over decades. So far, at least, the Higgs boson conforms well to the model's predictions, although there are intriguing hints that this could change as additional data are gathered.
No less incredible than the standard model is the effort that has been made towards its verification. Over the decades since the model was first put together, thousands of physicists have devoted their careers to it. They began with accelerators in university basements and have concluded at a 27-kilometre behemoth known as the Large Hadron Collider (LHC). Although undeniably European in character, the LHC and its four building-sized detectors are a global experiment, built by researchers and engineers from around the world. Like the theory they are helping to verify, the experimental apparatuses are pinnacle achievements -successful global collaborations unlike anything science has seen before, and very good models of how global scientific experiments should look in the future.
Everybody else grasped the significance of the moment, even if they didn't grasp the theory behind it. Praise and enthusiasm came from all corners: even the blustering tabloids and cable news stations briefly diverted from their reports of the week's banking scandals to herald the announcement.
But perhaps inevitably, questions were being raised even before the press conference to announce the discovery had come to an end. What is the Higgs good for? Was it worth all the trouble? And now that it has been found, what are physicists supposed to do?
In brief, the answers are: nothing; yes; and pop some champagne. Like great works of art, the discovery of the Higgs and the verification of the standard model are aesthetic achievements of humanity that deserve celebration. Governments might clamour for return on investment in science, but the Higgs discovery reminds us of the things that basic research is really about: curiosity, creativity and hard work. The particle needs no further justification, although with time, it could earn one, just as other great discoveries have in the past.
Sooner or later, the celebrations will end, and high-energy physicists will turn their attention to what to do next. It is not an easy time to face such an existential question: the global financial crisis means that money is tight, and without some fresh hints from the LHC, theorists will struggle to develop a framework that can exceed the standard model's exceptional power.
Some obvious lines of enquiry remain, however. Gravity, for example, continues to defy theoretical efforts to unify it with the other fundamental forces. And cosmological measurements suggest the existence of more things in heaven than are dreamt of in the standard model's philosophy -dark matter, which makes up 80% of the known matter, and dark energy, which could have an even larger contribution to the Universe. These are tricky questions, but the fact that they even exist should give hope to the next generation of physicists and to science-lovers everywhere. ■
